---
title: "Understanding the Market | AKESO-B surged over 6% in early trading, collaborating with the United States' Inovio Pharma to explore innovative treatments for glioblastoma with a new DNA drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277866495.md"
description: "Akeso-B rose over 6% in the morning session, as of the time of writing, it increased by 6.3%, priced at HKD 101.3, with a transaction volume of HKD 343 million. In terms of news, Akeso announced in collaboration with Inovio that they have reached a cooperation agreement to work with the world-renowned cancer research institution Dana Farber Cancer Institute and the leading medical group Mass General Brigham to jointly explore Akeso's globally innovative PD-1/CTLA-4 bispecific antibody Cadonilimab in combination with Inovio's DNA drug INO-5412 for the innovative treatment of glioblastoma (GBM). Dr. Yu Xia, founder, chairman, president, and CEO of Akeso, stated that Cadonilimab is the world's first approved bispecific antibody for tumor immunotherapy. Akeso is accelerating the global development of Cadonilimab through a diversified approach of \"independent development + global collaboration,\" deeply exploring the groundbreaking clinical value and international potential of Cadonilimab as a cornerstone drug for immunotherapy, and promoting the development of tumor immunotherapy in the 2.0 era"
datetime: "2026-03-05T02:38:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277866495.md)
  - [en](https://longbridge.com/en/news/277866495.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277866495.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277866495.md) | [繁體中文](https://longbridge.com/zh-HK/news/277866495.md)


# Understanding the Market | AKESO-B surged over 6% in early trading, collaborating with the United States' Inovio Pharma to explore innovative treatments for glioblastoma with a new DNA drug

According to Zhitong Finance APP, Akeso-B (09926) rose over 6% in early trading, and as of the time of writing, it is up 6.3%, priced at HKD 101.3, with a transaction volume of HKD 343 million.

In terms of news, Akeso announced in collaboration with Inovio that they have reached a cooperation agreement to jointly explore innovative treatments for glioblastoma (GBM) using Akeso's globally pioneering PD-1/CTLA-4 bispecific antibody Cadonilimab in combination with Inovio's DNA drug INO-5412, alongside the world-renowned cancer research institution Dana Farber Cancer Institute and the leading medical group Mass General Brigham.

Dr. Xia Yu, founder, chairman, president, and CEO of Akeso, stated that Cadonilimab is the world's first approved bispecific antibody for tumor immunotherapy. Akeso is accelerating the global development of Cadonilimab through a diversified approach of "independent development + global collaboration," deeply exploring the groundbreaking clinical value and international potential of Cadonilimab as a cornerstone drug for immunotherapy, and promoting the development of tumor immunotherapy in the 2.0 era

### Related Stocks

- [AKESO (09926.HK)](https://longbridge.com/en/quote/09926.HK.md)
- [Inovio Pharmaceuticals, Inc. (INO.US)](https://longbridge.com/en/quote/INO.US.md)

## Related News & Research

- [CICC Remains a Buy on Akeso, Inc. (9926)](https://longbridge.com/en/news/281674709.md)
- [INOVIO Announces Pricing of $17.5 Million Public Offering | INO Stock News](https://longbridge.com/en/news/281527787.md)
- [What's Behind The Drop In Inovio Pharmaceuticals Stock Today?](https://longbridge.com/en/news/281547274.md)
- [Inovio Pharmaceuticals Suspends Existing At-the-Market Stock Program](https://longbridge.com/en/news/281512814.md)
- [18:19 ETINO Deadline: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit](https://longbridge.com/en/news/281581465.md)